Faslodex 500mg Multiple Dose Tolerability Study in BC Patients

An Open, Multicentre Phase I Clinical Study to Assess the Tolerability of Fulvestrant 500 mg in Postmenopausal Women With Hormone Receptor Positive Advanced or Recurrent Breast Cancer

The primary objective of this study is to assess the tolerability of 500mg fulvestrant in postmenopausal women with hormone receptor positive, advanced or recurrent breast cancer

Inclusion Criteria:

• Provision of written informed consent
• Postmenopausal woman who fulfils any one of the following criteria:
• Histological or cytological confirmation of breast cancer
• Estrogen receptor positive (ER+) or progesterone receptor positive (PgR+).

Exclusion Criteria:

• Having received any one of the following therapy for advanced or recurrent breast cancer
• 2 or more regimens of hormonal therapy or immunotherapy or 2 or more regimens of chemotherapy, etc